Diagnosis and Management — Clinical Quick Reference
Clinical findings are non-specific and overlap with many other conditions. PE should be suspected when:
VTE risk varies with type of risk factor. Major trauma, surgery, lower-limb immobilization, and malignancy carry highest risk. Oral contraceptives and hormone replacement therapy significantly increase VTE risk in women.
The diagnostic workup relies on integration of clinical probability, D-dimer, and imaging tests (primarily CTPA). Structured diagnostic algorithms optimize both sensitivity (avoiding missed PE) and specificity (avoiding unnecessary treatment).
IA The diagnostic strategy should be based on clinical probability, assessed either by clinical judgment or by validated prediction rules (Wells score, Geneva score, or Hestia criteria).
Clinical evaluation combined with predisposing factors determines baseline probability. This can be classified implicitly or using explicit rules, with the revised Geneva score and Wells score being most validated. Classification into low/intermediate/high probability helps guide subsequent testing.
| Pre-Test Probability | Implicit Clinical Judgment | Revised Geneva (Points) | Wells Score (Points) |
|---|---|---|---|
| Low | PE unlikely | 0–1 | 0–2 |
| Intermediate | PE possible | 2–4 | 3–4 |
| High | PE likely | ≥5 | ≥5 |
| Criterion | Points |
|---|---|
| Clinical signs of DVT (leg swelling, pain) | 3 |
| Alternative diagnosis less likely than PE | 3 |
| Heart rate >100 bpm | 1.5 |
| Immobilization ≥3 days or surgery in past 4 weeks | 1.5 |
| Previous DVT or PE | 1.5 |
| Haemoptysis | 1 |
| Malignancy (treatment ongoing or <6 months ago) | 1 |
Interpretation: PE-unlikely: 0–4 points | PE-likely: ≥5 points
| Item | Original Version (Points) | Simplified Version (Points) |
|---|---|---|
| Previous PE or DVT | 3 | 1 |
| Heart rate 75–94 bpm | 3 | 1 |
| Heart rate ≥95 bpm | 5 | 2 |
| Surgery or fracture within past month | 2 | 1 |
| Haemoptysis | 2 | 1 |
| Active cancer | 2 | 1 |
| Unilateral lower-limb pain | 3 | 1 |
| Unilateral lower-limb oedema | 4 | 1 |
| Age ≥65 years | 1 | 1 |
Interpretation — Original: Low 0–3 | Intermediate 4–10 | High ≥11
Interpretation — Simplified: Low 0–1 | Intermediate 2–4 | High ≥5
IA Plasma D-dimer measurement, preferably using highly sensitive assays, is recommended in outpatients/emergency department patients with low or intermediate clinical probability, or those PE-unlikely, to reduce need for unnecessary imaging.
2aB As an alternative to fixed D-dimer cutoff, age-adjusted cutoff (age × 10 µg/L for patients aged >50 years) should be considered for excluding PE in patients with low or intermediate clinical probability, or those PE-unlikely.
IA In outpatient/emergency department settings, point-of-care D-dimer assays (on-site testing) may offer advantages over centralized laboratory testing, provided sensitivity and negative predictive value meet defined thresholds (≥85% and ≥98%, respectively).
Haemodynamic instability defines acute high-risk PE requiring emergency intervention. Precise definition is critical for guiding management intensity.
| Category | Definition |
|---|---|
| Cardiac Arrest | Need for cardiopulmonary resuscitation |
| Obstructive Shock | Systolic BP <90 mmHg or vasopressors required to achieve BP ≥90 mmHg despite adequate filling status; end-organ hypoperfusion (altered mental status, cold/clammy skin, oliguria, increased serum lactate) |
| Persistent Hypotension | Systolic BP <90 mmHg or BP drop ≥40 mmHg lasting >15 min not due to arrhythmia, hypovolaemia, or sepsis |
The PESI integrates clinical and baseline parameters to assess 30-day mortality risk in patients without haemodynamic instability. Two versions available: original (11 parameters) and simplified sPESI.
| PESI Class | Points Range | 30-Day Mortality Risk |
|---|---|---|
| I (Low) | ≤65 | 0–1% (95% CI 0.0–2.1%) |
| II | 66–85 | 1.7–3.5% |
| III | 86–105 | 3–7.1% |
| IV | 106–125 | 4.0–11.4% |
| V (High) | >125 | 10.0–24.5% |
2aB Assessment of RV function by imaging or laboratory biomarkers should be considered, even in presence of low PESI or negative sPESI.
| Risk Category | Haemodynamic Instability | RV Dysfunction | Myocardial Injury (Troponin/BNP) |
|---|---|---|---|
| High-Risk PE | + (present) | + or – | + or – |
| Intermediate-High PE | – (absent) | + (present) | + (elevated) |
| Intermediate-Low PE | – (absent) | + (present) | – (normal) |
| Low-Risk PE | – (absent) | – (absent) | – (normal) |
Acute treatment aims to (1) prevent haemodynamic decompensation and death, (2) prevent recurrent PE, and (3) facilitate recovery. Management intensity depends on risk stratification: high-risk PE requires emergency intervention, intermediate-risk requires close monitoring, and low-risk can often be managed with early discharge.
IC Supplemental oxygen is indicated in patients with SaO₂ <90%. In severe hypoxaemia, high-flow oxygen, non-invasive ventilation (e.g., CPAP), or mechanical ventilation may be needed to correct ventilation-perfusion mismatch and maintain oxygenation.
In acute RV failure (high-risk PE), haemodynamic support strategies are tailored to the pathophysiology:
IC In patients with high or intermediate clinical probability of PE (or PE-unlikely with positive imaging), anticoagulation with UFH (unfractionated heparin) including weight-adjusted bolus, should be initiated without delay.
IA When anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a VKA, as first-line oral anticoagulant treatment.
VKAs (e.g., warfarin) remain an option for patients who cannot use NOACs. Requires bridging with parenteral anticoagulant and INR monitoring (target INR 2–3).
IB Systemic thrombolytic therapy is recommended for high-risk PE (confirmed by haemodynamic instability) to improve pulmonary perfusion and RV function, reduce mortality.
| Thrombolytic Agent | Dosing Regimen | Key Notes |
|---|---|---|
| Alteplase (rtPA) | 100 mg IV over 2 hours (standard); 50 mg over 1 h (accelerated) | Most widely used; can be accelerated in high-risk situations |
| Tenecteplase | Weight-based: 30–50 mg IV bolus over 10 sec | Fibrin-specific; single-bolus administration more convenient |
| Streptokinase | 250,000 IU loading dose 30 min, then 100,000 IU/h × 12–24 h | Older agent; rarely used; requires aPTT monitoring |
| Urokinase | 4400 IU/kg loading × 10 min, then 4400 IU/kg/h × 12–24 h | Alternative if allergic to other agents |
Absolute: History of haemorrhagic stroke or stroke of unknown origin; ischaemic stroke in previous 6 months; central nervous system neoplasm; major trauma, surgery, or head injury in previous 3 weeks; active bleeding or bleeding diathesis
Relative: Transient ischaemic attack in previous 6 months; oral anticoagulation; pregnancy or first postpartum week; non-compressible puncture sites; traumatic resuscitation; refractory hypertension; advanced liver disease; active peptic ulcer
2aC Catheter-directed thrombolysis (CDT) or ultrasound-assisted thrombolysis may be considered as an alternative to systemic thrombolysis in intermediate-risk PE patients with contraindications to systemic thrombolysis or in selected cases of intermediate-risk PE.
2aC Surgical pulmonary embolectomy should be considered as an alternative to rescue thrombolysis in high-risk PE in whom thrombolysis has failed or is contraindicated, and in selected intermediate-risk PE if expertise is available.
IA Therapeutic anticoagulation for ≥3 months is recommended for all patients with PE (regardless of provocation status).
| Risk Category | Estimated Recurrence Risk | Duration Recommendation |
|---|---|---|
| Provoked PE (major) | <3% per year | 3 months of anticoagulation |
| Provoked PE (minor) | 3–8% per year | ≥3 months; consider extension based on clinical judgment |
| Unprovoked PE (first episode) | ≥8% per year | ≥3 months; extension recommended based on risk factors |
| Recurrent PE/VTE | High | Indefinite anticoagulation |
| PE with cancer | High | LMWH/DOAC or indefinite; reassess as cancer status evolves |
2aA Extended oral anticoagulation of indefinite duration should be considered for patients presenting with a first episode of PE associated with a persistent risk factor (e.g., malignancy or antiphospholipid antibody syndrome).
2aC Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE without identifiable risk factor (unprovoked).
PE is a rare but potentially fatal complication of pregnancy, responsible for maternal death in high-income countries. VTE risk is increased 4–5-fold during pregnancy and peaks in postpartum period (up to 6 weeks post-delivery).
IB Formal diagnostic assessment with validated methods is recommended (PE is suspected during pregnancy).
IB A therapeutic fixed dose of LMWH based on early pregnancy body weight is recommended therapy for PE in the majority of pregnant women without haemodynamic instability.
2aC Thrombolysis or surgical pulmonary embolectomy should be considered for pregnant women with high-risk PE.
Postpartum Management: Anticoagulation should be continued for ≥6 weeks after delivery; longer duration (3 months) recommended if unprovoked PE.
Patients with active cancer have significantly elevated VTE risk (3–7-fold higher than general population). Cancer-related VTE includes provoked PE/DVT and may be influenced by cancer type, stage, and treatment.
2aA For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be considered for the first 6 months over VKAs.
2aB Edoxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer.
2aC Rivaroxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer.
2aB For patients with PE and cancer, extended anticoagulation (beyond the first 6 months) should be considered for an indefinite period or until cancer is cured.
Integrated clinical tools help quantify PE risk and guide management decisions. Use alongside clinical judgment.
7-item clinical prediction rule for PE probability: 0–4 (PE-unlikely) vs. ≥5 (PE-likely)
9-item scoring system with original and simplified versions for PE probability assessment
11-parameter prognostic score predicting 30-day mortality risk in PE (Classes I–V)
Estimates renal function to guide anticoagulation dosing adjustments
Estimates glomerular filtration rate for renal impairment assessment
7-item bleeding risk assessment tool to guide anticoagulation safety decisions